Neuroleptic drug effect on platelet monoamine oxidase and plasma amine oxidase in schizophrenia.
Activity levels of platelet monoamine oxidase (MAO) and plasma amine oxidase (PAO) were determined in eight chronic schizophrenic patients who had been treated with neuroleptic drugs for 3 months. The mean reduction in platelet MAO activity was 18.6%. The extent of decrease was statistically significant. The reduction in enzyme activity was unrelated to serum iron levels. PAO activity was unaltered. The implications for schizophrenia research are discussed.
D000328:Adult; D006631:Amine Oxidase (Copper-Containing); D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects* / Q000201:enzymology; D002746:Chlorpromazine / Q000627:therapeutic use; D005260:Female; D005476:Fluphenazine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008995:Monoamine Oxidase / Q000097:blood*; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000097:blood*; D012559:Schizophrenia / Q000188:drug therapy* / Q000201:enzymology
D014150:Antipsychotic Agents; D006631:Amine Oxidase (Copper-Containing); D008995:Monoamine Oxidase; D000587:Oxidoreductases Acting on CH-NH Group Donors; D006220:Haloperidol; D005476:Fluphenazine; D002746:Chlorpromazine